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Seroepidemiological study on the spread of SARS-CoV-2 in 
populations in especially affected areas in Germany –  
Study protocol of the CORONA-MONITORING lokal study
Abstract
At a regional and local level, the COVID-19 pandemic has not spread out uniformly and some German municipalities 
have been particularly affected. The seroepidemiological data from these areas helps estimate the proportion of the 
population that has been infected with SARS-CoV-2 (seroprevalence), as well as the number of undetected infections 
and asymptomatic cases.
In four municipalities which were especially affected, 2,000 participants will be tested for an active SARS-CoV-2 infection 
(oropharyngeal swab) or a past infection (blood specimen IgG antibody test). Participants will also be asked to fill out a 
short written questionnaire at study centres and complete a follow-up questionnaire either online or by telephone, 
including information on issues such as possible exposure, susceptability, symptoms and medical history.
The CORONA-MONITORING lokal study will allow to determine the proportion of the population with SARS-CoV-2 
antibodies in four particularly affected locations. This study will increase the accuracy of estimates regarding the scope 
of the epidemic, help determine risk and protective factors for an infection and therefore also identify especially exposed 
groups and, as such, it will be crucial towards planning of prevention measures.
  SARS-COV-2 · COVID-19 · SEROLOGICAL STUDY · CROSS-SECTIONAL STUDY · STUDY PROTOCOL · CORONA HOTSPOT
1. Introduction
In December 2019, the first cases of a lung disease caused 
by a new coronavirus were described in Wuhan, China. 
Since then, SARS-CoV-2 (Severe Acute Respiratory Syn-
drome Coronavirus 2) infections and cases of COVID-19 
(Coronavirus Disease 2019) have spread worldwide, caus-
ing a pandemic with over 12 million confirmed diagnoses 
and 560,000 deaths. Germany has so far registered 195,000 
SARS-CoV-2 infections, causing 9,064 fatalities either of or 
related to the development of COVID-19 (as at 13 July 2020) 
[1]. Federal states which are particularly affected with a high 
cumulative incidence (cases per 100,000 inhabitants) 
included Bavaria (20 cases per 100,000 inhabitants), 
Saarland (17.5 cases per 100,000 inhabitants) and Baden- 
Württemberg (16.6 cases per 100,000 inhabitants). 
In Germany, the distribution of the COVID-19 pandemic 
differs widely across all regions and locations. Following a 
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lence of past SARS-CoV-2 infections in the population. In 
the COVID-19 Case-Cluster-Study, which was conducted 
in the Gangelt municipality (North Rhein-Westphalia) 
between March and April 2020, researchers reported an 
IgG seroprevalence of 15.5% and a factor of five for unde-
tected infections (with regard to the number of registered 
SARS-CoV-2 cases) [11]. However, due to a different 
method the comparability of results is limited. 
Due to the high number of cases, seroepidemiological 
data from particularly affected locations facilitates a rather 
accurate estimate of past infections and provides a good 
indication of the number of undetected SARS-CoV-2 infec-
tions. Furthermore, research into the risk and protective 
factors for an infection help identify high risk groups, and 
this is crucial in terms of putting prevention measures in 
place. Conclusions related to the burden of disease, the 
number of asymptomatic infections, as well as the 
dynamic of infections can be drawn and, in part, trans-
ferred to locations not as impacted by the epidemic. 
In the context of the CORONA-MONITORING lokal 
study, antibody prevalence and the proportion of active 
infections was determined in four municipalities particu-
larly affected by SARS-CoV-2 and a cumulative incidence 
of over 500 registered cases per 100,000 inhabitants 
over a timespan of one month.
At each survey location the study aims to:
1. Determine seroprevalence (proportion of the popula-
tion that has been in contact with the virus) for each 
survey location by age group and sex,
2. Calculate the proportion of undetected infections, 
3. Identify the proportion of asymptomatic infections. 
local outbreak caused by a business woman visiting 
Bavaria from China at the beginning of the year [2], sub-
sequent infections were mainly due to people returning 
from Italian and Austrian ski resorts. Some municipali-
ties in Germany have registered an overproportionate 
number of COVID-19 infections. Local infection hotspots 
have often been related to events where a greater trans-
mission of the virus occurred such as carnival parties, 
concerts or other festive events [3–7]. Internationally, this 
phenomenon of indoor events as a possible place of 
transmission for SARS-CoV-2 infections is familiar [8, 9]. 
Further relevant situations that drive transmission and 
are related to living and/or working conditions include 
crowded shared accommodation or working in the meat 
industry [10]. 
The available data on the spread of SARS-CoV-2 infec-
tions in Germany has so far been based on confirmed 
SARS-CoV-2 case numbers reported to the local health 
authorities in line with Germany’s Protection against 
Infection Act (IfSG). These cases are diagnosed by poly-
merase chain reaction (PCR) tests. Based on current sci-
entific data, however, an unknown proportion of SARS-
CoV-2 infections can be assumed to take an asymptomatic 
or mild course, which means that many subclinical or 
mild infection courses are not diagnosed as SARS-CoV-2 
infections. Furthermore, in line with the recommenda-
tions from the Robert Koch Institute (RKI), the European 
Centre for Disease Prevention and Control (ECDC) and 
the World Health Organization (WHO), PCR tests are 
conducted only with symptomatic patients likely to test 
positive for SARS-CoV-2. So currently, reported case num-
bers do not provide a reliable estimate of the actual preva-
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2.1 Study design and sampling
Study design
The CORONA-MONITORING lokal study is a popula-
tion-based, seroepidemiological observation study that will 
conduct cross-sectional examinations at four locations in 
Germany which were particularly affected by the COVID-19 
epidemic. An ongoing acute transmission of SARS-CoV-2 
would call for a repetition of cross-sectional surveys or 
supplementing the results with longitudinal examinations 
with serial serological testing and interviews with a select-
ed group of participants.
Sample
The study will be conducted at four municipalities particu-
larly affected by the COVID-19 epidemic (defined as a 
reported cumulative SARS-CoV-2 incidence of over 500 
cases per 100,000 inhabitants one month before the begin-
ning of data collection) among 2,000 individuals for each 
study. Municipalities are selected with regard to the epi-
demiological developments shortly before the local start 
of the study. The selection criteria for municipalities are a 
past or ongoing transmission as well as the willingness of 
local authorities to contribute towards the study. 
A random sample from population registries is provided 
to the RKI. This includes adults aged 18 years and older 
with no upper age limit who are registered residents in one 
of the surveyed municipalities. Proportional sampling is 
applied, i.e. population registries are asked to provide 
4,000 to 5,000 randomly drawn addresses not stratified by 
sex and/or age group. Based on an expected response rate 
Due to the limited number of cases, some analyses can-
not be conducted for each location; but will be conducted 
with aggregated data of all four sample points: 
1. Sensitivity analyses of infection rates and the proportion 
of undetected infections by taking into account the data 
of non-responders, as well as the data on reported and/
or deceased cases.
2. Presenting infection rates differentiated by exposure 
contexts (living conditions including household size, 
having children to care for where applicable; contact 
intensity in the work environment (during the pandemic) 
and use of public transport).
3. Calculation of the proportion of undetected cases relative 
to the number of reported cases differentiated by risk 
group status (age group 65 years and older, pre-existing 
conditions) and age group, sex and education.
4. Differentiation of symptomatic infections by sex and/or 
age group, as well as by exposure contexts (living con-
ditions including household size, having children to 
care for where applicable; contact intensity in the work 
environment (during the pandemic) and use of public 
transport).
5. Identification of risk and protective factors for a SARS-
CoV-2 infection and the extent to which it is embedded in 
the respondent’s living, family and occupational situation.
6. Calculation of infection mortality (where case numbers 
were sufficiently high, stratification by age and sex).
Furthermore, the study aims to create a basis for longi-
tudinal studies that will potentially facilitate follow-ups on 
the possible sequelae of people who have experienced a 
SARS-CoV-2 infection.
The spread of SARS-CoV-2 
infections differs widely 
across Germany.
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The individuals selected randomly from the population 
registries of the corresponding municipalities are first invit-
ed in writing to take part in the study. They receive an invi-
tation by mail with materials informing them about the study 
(study information, data protection declaration, consent 
form and a personalised ‘participation schedule’). Those 
who are willing to participate can make an appointment at 
the study centres choosing from the days scheduled for 
the study either via an online calendar or by phone at the 
study hotline (Figure 1). Depending on the response rate, a 
re minder is sent to people who have been invited but neither 
responded nor made an appointment after about one week.
People in the age group 60 years and older, who have been 
defined as a high risk group for a COVID-19 infection, receive 
an adapted invitation letter that explicitly offers the option of 
a home visit [12]. A telephone hotline with specially trained 
staff has been established to take into account the individual 
needs and requests of elder and elderly people in the run-up 
to home visits. People aged under 60 years with limited mobil-
ity or who fear an infection and therefore cannot or do not 
want to go to a study centre, are offered home visits upon 
request as a measure to limit the effects of selection bias.
People who contact survey staff and refuse to take part 
are asked to state the reasons for their decision. People who 
do not react to the letter and with whom no contact is there-
fore established will be chased-down after the field work 
has been completed and will be asked to fill out a non-re-
sponder questionnaire to estimate the representativeness 
of the study sample.
of between 60% and 70%, at first 2,900 randomly selected 
individuals are then contacted in writing. If the response 
rate is lower than expected, further random samples will 
be drawn within sex and/or age groups underrepresented 
among participants from the first sample. When further 
survey waves are conducted, this step is repeated. The 
municipalities that have been selected so far are Kupferzell 
(Baden-Wuerttemberg), Bad Feilnbach (Bavaria) and 
Straubing (Bavaria).
Inclusion and exclusion criteria
Individuals will be included 
  if they are 18 years or older,
  are registered residents of one of the four study munic-
ipalities,
  can provide written consent to participate in the study, 
or, where necessary, written consent is provided by a 
legal representative, 
  are able to take part in the interviews (where necessary 
with the help of relatives) and the examinations at the 
study centres or during home visits.
People who lack the necessary German language skills 
or where it is unclear whether they understand the study 
information leaflets or the consent forms are excluded from 
participating. Currently, we are considering translating the 
survey material into English and further locally relevant 
languages and seeking the services of interpreters.
Local infection hotspots  
can apparently often be 
traced to certain events or 
situations where pathogen 
transmission is increased.
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In preparation for the CORONA-MONITORING lokal 
study the following training sessions were organised:
   overview of the study objectives
  overview of SARS-CoV-2 and COVID-19
  measures of infection protection (including disinfecting 
measures)
  working with personal protective equipment
  participant reception and informed consent 
  conducting home visits 
  taking blood specimens and oropharyngeal swabs
  specimen processing, storage and transport
  break periods
All the staff involved in the study took part in these train-
ing sessions (training in taking blood samples and con-
ducting oropharyngeal swabs only for the corresponding 
staff).
Study centres
Per municipality, one to two temporary study centres will 
be established. Centres will consist of a bus for examina-
tions and a rented space. The latter will count with one to 
two receptions and two examination rooms as well as a 
laboratory (with a centrifuge and a laptop). The bus for 
examinations provides two further examination rooms. 
Study staff
The study staff includes physicians, staff who have com-
pleted training in a medical profession (health care and 
nursing, geriatric care, medical assistants), nutritionists 
and administrative employees. All in all, the study teams 
consist of around 25 individuals. 
Figure 1
CORONA-MONITORING lokal study 
recruitment procedure
Source: Own depiction
Compiling materials and  
sending invitations by post
Optional: email confirmation of appointment
Optional: text message reminder one day 
before appointment
Study participation
Registration via telephone hotline Refusal of participation by telephone/ 
registering reason for refusal
Registration via online appointment
As part of the study, 2,000 
participants per location are 
examined in a temporary 
study centre or during home 
visits for an active 
SARS-CoV-2 infection  
as well as SARS-CoV-2  
IgG antibodies.
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(Fa. Becton Dickinson GmbH, Heidelberg) with separating 
gel and clotting activator is used.
Blood samples and oropharyngeal swabs are immedi-
ately taken to the laboratory. The swabs are stored in a 
fridge and blood samples centrifuged for 12 minutes at 
4.400 RPM (corresponding to 3000 x g) 30 to 45 minutes 
after being taken in an Eppendorf model 5702 lab bench 
centrifuge (Eppendorf AG, Hamburg) and filled into two 
serum tubes (screw caps 10 ml PP sterile, Sarstedt Ag & 
Co. KG, Rheinbach) and then also stored in the fridge. 
Consent forms and written questionnaires are sent with 
the specimens collected and stored at 4°C in actively 
cooled boxes (Dometic Group CoolFreeze CF 35; Dometic 
Germany GmbH, Elmsdetten) with a daily shuttle to the 
RKI for further processing.
Home visits are conducted by teams of two people: one 
person to take specimens and one person as a driver. Pro-
cedures during home visits match those at the study cen-
tres. After the home visit, the driver takes the consent form, 
the questionnaire and the specimens to the study centre 
for further processing.
Around one to two weeks after the examination, a fol-
low-up interview via an online questionnaire is scheduled. 
If a participant prefers, this interview can also be conducted 
as a telephone interview (Table 1).
Infection prevention during data collection 
At the study centres and during home visits, participants 
are asked to wear facemasks and are, if necessary, provid-
ed with one. Participants are also asked to maintain phys-
ical distance. During specimen collection, the examination 
staff wear personal protective equipment and particle 
Study procedure 
Figure 2 shows the study procedure. Upon arrival at the 
study centre, participants identify themselves with a valid 
identity document. Reception staff then informs them 
about the objectives and purpose of the study (as well as 
the fact that participation is voluntary) and answers any 
questions that arise. Together with the invitation, partici-
pants receive a consent form, but are asked to sign it only 
once they arrive at the study centre.
Participants then fill out a short questionnaire, provide 
a blood sample and an oropharyngeal swab. Oropharyn-
geal swabs are taken out of the opened mouth using the 
Copan Group (Brescia, Italy) Copan Liquid Amies Elution 
Swab transport system. For venous blood collection, the 





At the study centre
After visiting the study centre
1 to 2 weeks after  
participation in the study
About 4 weeks after  
participation in the study
Reception and  
informed consent












PCR = Polymerase chain reaction
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filtering FFP2 masks. Examination rooms are regularly 
cleaned, aired and surfaces disinfected after every exami-
nation. Participants with cold symptoms are asked not to 
come to the study centre and whenever possible 
an appointment for a home visit is made.
Communication of results
Participants receive their PCR laboratory and antibody test 
results in the form of a pseudonymised result report. The 
following values are tabulated with their corresponding 
reference intervals: 
   PCR test result for SARS-CoV-2 virus material on the 
oropharyngeal swab (positive/negative). 
  ELISA (enzyme-linked immunosorbent assay) for SARS-
CoV-2 IgG antibodies in the blood (positive/marginal 
positive/negative).
Before communicating the results, a trained study 
physician conducts a plausibility check for the test results. 
The administrative survey staff send out the pseu-
donymised result report accompanied by a personalised 
letter. Notifiable laboratory results are forwarded to the 
responsible health office (in writing) within 24 hours and 
the participant is informed about the result by the medi-
cal study staff (by telephone and in writing). In addition, 
infected participants receive the RKI’s information leaflet 
on self-isolation.
Quality assurance (QA)
Quality assurance measures during the study procedures 
are organised through an internal QA taskforce, which has 
previously been established at the RKI for other studies. 
Table 1 
CORONA-MONITORING lokal study,
content of the questionnaires
Source: Own depiction
Short questionnaire 
(SAQ-P provided at the study centre or during home visits)
Age and sex
Respiratory symptoms
COVID-19 diagnosis and care 
Quarantine and reasons for quarantine
Travel anamnesis
Compliance with physical distancing





Work situation (for example contact with patients)
Education, employment status, household
Detailed questionnaire 
(follow-up questionnaire as SAQ-W or CATI)
Age and sex
Diseases, medications, vaccinations
Testing and medical diagnosis of COVID-19 
COVID-19 symptoms
Health care (for example not utilising healthcare services) 
Health behaviour (for example physical activity or alcohol consumption)
Mental and psychosocial health (for example depression)
Social relations and contacts
Everyday life and leisure time (for example compliance with hygiene 
and physical distancing rules, wearing facemasks)





Health at higher age (60 years and older)
Acceptance of containment measures 
Risk perception
Detailed sociodemography
SAQ-P = self-administered questionnaire on paper 
SAQ-W = web based self-administered questionnaire 
CATI = computer-assisted telephone interview
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throats and difficulties with conducting swabs, the actual 
sensitivity of the test is below 100%.
To detect IgG antibodies against the new coronavirus, 
the study uses Euroimmun’s (Euroimmun Medizinische 
Labordiagnostika AG, Lübeck) commercial laboratory test 
‘Anti-SARS-CoV-2-ELISA (IgG)’. The test has been validated 
by a number of laboratories (for example by the National 
Consultant Laboratory for Coronaviruses at the Charité- 
Universitätsmedizin Berlin, Professor Christian Drosten). 
With a sensitivity of 93.8% and a specificity of 99.6%, the 
test is of high quality and of low cross-reactivity (Info box). 
The use of this test in numerous further national and inter-
national studies makes comparisons of seroprevalence 
easier. The analyses are automated using Euroimmun’s 
high throughput ‘EUROLab Workstation ELISA’ analyser.
As in all test procedures with a specificity of <100% – in 
particular when seroprevalence in the population is low – 
a certain proportion of false positives is inevitable. A 
neutralisation test was therefore performed on all ELISA 
reactive samples at the National Consultant Laboratory for 
Coronaviruses at the Charité-Universitätsmedizin Berlin. 
The result of this test was used for scientific evaluation. The 
exact method of this plaque reduction neutralisation test 
is described here [14].
IgG antibody tests indicate whether someone has in the 
past had contact with the new coronavirus. Whether, and 
if yes, for how long an individual is then immune to the 
new coronavirus, cannot yet be safely said. Even people 
with a positive antibody test should therefore keep to the 
recommended hygiene and behaviour rules in their private 
and professional contexts. The same in any case applies 
to people without a positive antibody test.
At all stages of data collection, Standard Operating 
Procedures (SOP) have been defined. The study team receives 
training based on a fixed training protocol before data collec-
tion begins. Furthermore, before actual data collection, a pre-
test was run to test and where necessary adapt all steps. Con-
tinuous supervision by the leading field staff and the QA team 
during data collection is supplemented by regular further 
training provided to the study team; these training sessions 
are firmly anchored within the schedule. Where necessary, 
additional individual training sessions can be carried out. 
All the steps during laboratory examinations are docu-
mented (from blood sample collection to arrival of the 
specimens at the RKI’s central epidemiological laboratory) 
to accomplish QA and to make sure that samples are not 
mixed up.
2.3 Survey methods and content
Laboratory diagnostics 
Two in-house PCR tests are used to test for the SARS-CoV-2 
genome. Test 1 detects the E-gene adapted to [13] and is 
monitored with a simultaneous PCR to offset possible 
errors with ribonucleic acid (RNA) extraction as well as a 
possible PCR inhibition. Test 2 is specific to SARS-CoV-2, 
is located in the ORF1ab region and can confirm not only 
the presence of the SARS-CoV-2 genome but also cellular 
nucleic acids and therefore successful sample extraction. 
Under the test conditions applied, both SARS-CoV-2 tests 
have a limit of detection of <10 genomes/reaction and 
therefore, at the analytical level, have a sensitivity and speci-
ficity (Info box) of nearly 100%. Due to the relatively short 
timeframe during which the virus is detectable in patients’ 
Info box:  
Sensitivity, specificity and cross-reactivity
Sensitivity indicates how well a test can correctly 
identify a person with SARS-CoV-2 specific anti-
bodies.
Specificity indicates how well a test can correctly 
identify a person without SARS-CoV-2 antibodies.
Cross-reactivity describes the capacity of antibodies 
to bind to antigens with similar docking sites. With 
regard to SARS-CoV-2, this means that an antibody 
does not bind only to SARS-CoV-2 but potentially 
also to other coronaviruses spread in Germany 
(such as HCoV-OC43, HCoV-HKU1).
Journal of Health Monitoring 2020 5(S5)
Seroepidemiological study on the spread of SARS-CoV-2 in populations in especially affected areas in GermanyJournal of Health Monitoring
10
FOCUS
Statistical analysis and estimation of sample size
Data analysis involved applying a weighting variable to bet-
ter reflect the structure of the general population in the 
selected municipalities regarding age and sex. In addition, 
weighting is applied regarding education by sex and age 
group. The marginal distribution is approximated referring 
to the administrative district based on micro census data 
2017 [21].
Weighting allows true but unknown parameters in the 
population to be better reflected although it is also related 
to an increase in the variance of estimators gained in the 
study. Based on experiences made in previous studies and 
assuming a relatively high willingness to participate and 
low selectivity, we set this factor to estimate case numbers 
at 1.43 (=1/(70%), where 70% describes the ‘effectiveness’ 
of the weighting variable, a measure for the spread of 
weights). For younger adults (18- to 34-years-old) and the 
older age group (65 years and older) based on previous 
studies effectiveness is set slightly lower (at 60% and 65%, 
respectively) [22, 23].
Based on these assumptions, with a net sample of 
n=2,000 individuals we can achieve the accuracies given in 
Table 2 for the estimates of seroprevalence for the general 
population of the corresponding study location, as well as 
for the population stratified by age group. Estimates are pre-
sented for an estimated seroprevalence of 3%, 5%, 10% and 
15% in the general population with a distribution among age 
groups that corresponds to the distribution of reported cases 
in regions with a high number of infections (own calculation 
based on population registry data; as at end of March 2020).
If the requirement for estimate precision defines that 
the variation coefficient of the prevalence estimate is to be 
Interviews
Laboratory examinations to detect an acute or past SARS-
CoV-2 infection are supplemented by interviews with study 
participants to gain further information on a set of ques-
tions such as potential exposure, susceptibility, symptoms 
and medical history. Interviews consist of two parts: a 
short questionnaire that participants fill out either at the 
study centre or during home visits in the form of a written 
questionnaire, as well as a more detailed questionnaire 
that participants are asked to fill out one to two weeks 
after the appointment. Preferably, the administration is 
web-based, which means that participants receive access 
to an online questionnaire which they are asked to com-
plete. Participants that cannot or do not want to fill out 
this questionnaire online can complete it via a computer- 
assisted telephone interview (CATI). Table 1 summarises 
the content of both questionnaires. As far as possible, 
established survey instruments and validated scales are 
used [15–20], and these are complemented or modified to 
the specific survey mode and focus of the study. The ques-
tionnaire is adapted to reflect specific events that have 
taken place at each survey location and the periods of time 
people are asked to remember regarding the epidemio-
logically-relevant events at a specific location. Following 
data collection, all non-responders receive a non-respon-
der questionnaire to gain an understanding of their reasons 
for not taking part.
3. Expected results 
We now present the expected results and the statistical 
procedures involved in data analysis. 
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Descriptive analyses are first conducted for the following 
parameters:
  description of response and non-response,
  sociodemographic characteristics (at first age and sex; 
in analyses with follow-up interviews socioeconomic 
status, household composition, etc.),
  prevalence of SARS-CoV-2 IgG antibodies in blood sam-
ples, and/or positive oropharyngeal swab test in the 
corresponding population (at first stratified by age and 
sex, later by socioeconomic status and other relevant 
indicators),
less than one sixth (which is equivalent to requiring that 
the bottom limit of the confidence interval should be at 
least two thirds of prevalence), then all the expected con-
fidence intervals are in this sense acceptable for estimates 
regarding the general population. For the estimates strat-
ified by age group, this requirement is not met if seropreva-
lence is only 3%, or only 3% or 5% for the oldest age group. 
However, it is possible to increase the precision of the esti-
mators for individual age groups, if we group estimators 
for several particularly affected municipalities. Moreover, 
3% tends to be the lower limit for the seroprevalences that 
can be expected in particularly affected locations.
Population Age group Seroprevalence Expected width of the 95% confidence interval
years % %














50–64 6.9 4.6–10.2 
≥65 3.8 2.2–6.8 
Population by age group  
(expected seroprevalence: 10%)
18–34 12.4 9.4–16.3 
35–49 13.4 10.2–17.3
50–64 13.8 10.5–18.0 
≥65 7.7 5.1–11.4 
Population by age group  
(expected seroprevalence: 15%)
18–34 18.6 14.9–23.0 
35–49 20.1 16.2–24.5 
50–64 20.7 16.7–25.4 
≥65 11.5 8.3–15.8 
Table 2 
Expected accuracy of estimators for the 
(sero)prevalence of SARS-CoV-2 infections in 
the population aged 18 years and older in 
particularly affected locations in Germany
Source: Own depiction
Seroprevalence figures allow 
an estimate of the  
number of undetected and 
asymptomatic SARS-CoV-2 
infections.
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actually had an infection can help to estimate the number 
of undetected cases relative to the number of reported 
cases. This will provide a better idea of the local extent of 
the epidemic as well as the proportion of asymptomatic 
infections, and, by identifying active infections, the current 
infection dynamics. 
Currently, a number of seroepidemiological studies on 
SARS-CoV-2 are being conducted in municipalities particu-
larly affected [24, 25]. In the context of the COVID-19 
Case-Cluster Study, which was conducted during March 
and April in Gangelt, a municipality particularly affected by 
SARS-CoV-2 in the Heinsberg district (North Rhein-West-
phalia), an IgG-seroprevalence of 13.60% was described. 
After monitoring sensitivity (90.9%) and specificity (99.1%), 
seroprevalence was corrected to 14.11% [11]. Neutralisation 
tests were conducted but were not considered for the defi-
nition of antibody positive samples. When including acute 
confirmed infections as well as self-reported PCR-positive 
results the proportion of persons infected was described 
as 15.53%. A factor of five was estimated for the number 
of undetected cases. However, the methodology was 
not completely comparable with that of the CORONA- 
MONITORING lokal study, in particular because in our 
study only samples with a positive neutralisation test result 
were considered as confirmed positives.
The focused analysis of locations particularly affected 
with high rates of infection is an important contribution to 
understanding infection dynamics and the developments 
of population immunity while taking into account a diverse 
range of transmission dynamics. For example, the study 
can provide information on the likelihood of transmission, 
as well as on risk factors for a severe course of the disease, 
  prevalence of symptomatic and asymptomatic cases 
(based on test history),
  undetected case rate of antibody prevalence relative to 
the number of reported cases,
  antibody prevalence relative to local events visited.
Further and multivariate analyses
Further analyses look at the following questions: 
  Understanding SARS-CoV-2 risk and protective factors, 
as well as the extent to which they are embedded in the 
participants’ living, family and occupational situation.
  Sensitivity analysis of infection rates and the proportion 
of undetected cases that take into account non-responder 
data as well as data on reported cases and fatalities.
  Estimating the proportion of undetected cases for 
reported cases stratified by risk group yes/no (age group 
65 years and older, other conditions) and age group, sex, 
and education.
  Influencing factors and social contacts, mental health 
and everyday life.
  Asymptomatic infections stratified by sex and/or age 
group, as well as by exposure contexts (living conditions 
including household size, having children to care for 
where applicable; contact intensity in the work environ-
ment (during the pandemic) and use of public transport).
  Infection fatality stratified by age and sex.
4. Discussion
Studies in locations particularly affected by SARS-CoV-2 
can contribute towards a better understanding of the 
spread of the infection. The proportion of people who have 
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of 1.3%, a Germany-wide study is being planned to better 
estimate seroprevalence in the general population. A fur-
ther study is being conducted to accompany the re-open-
ing of childcare facilities that will provide answers on the 
role of children (aged 1 to 6) in the transmission of the 
disease [28].
In the context of the CORONA-MONITORING lokal 
study, SARS-CoV-2 seroprevalence is determined for four 
particularly affected locations. Findings can contribute to 
a better understanding of the local infection dynamics, but 
also allow comparisons of the local situations. A broader 
analysis of the data will allow us to determine risk and pro-
tective factors for an infection and a severe disease course 
and therefore identify high risk and exposure groups, which 
is essential for the planning of prevention measures.
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which are relevant not only to the local development of 
infections. Additional longitudinal studies with repeated 
serological testing of population subsamples can, due to 
the expected greater number of cases, provide information 
on the development of the epidemic and immunity of the 
population over time. Furthermore, we can also keep track 
of people who have tested positive for SARS-CoV-2 anti-
bodies, which should provide findings on the long-term 
effects of COVID-19. However, as these studies are focused 
on local hotspots and population structures, the results 
cannot be transferred to the general population and stud-
ies in particularly affected municipalities therefore cannot 
indicate the prevalence of SARS-CoV-2 antibodies in the 
general population in Germany. Possible limitations of the 
CORONA-MONITORING lokal study are a potential selec-
tion bias (only German speakers) which hopefully can be 
countered in the future by providing materials in several 
languages and interpreters. Recall bias is also a potential 
issue because many questions refer to the long time period 
since the beginning of the COVID-19 epidemic in Germany. 
A further point of discussion relates to how long SARS-
CoV-2 antibodies remain detectable, as some studies indi-
cate a decrease of antibody titers over time [26]. Still, sero-
surveys in particularly affected municipalities remain 
important to understand the dynamics of the COVID-19 
pandemic. At the Robert Koch Institute, along with the 
CORONA-MONITORING lokal study, three further studies 
to determine seroprevalence are being conducted to 
achieve a more complete picture of infection dynamics. In 
addition to serological analyses of blood donor samples 
for SARS-CoV-2 antibodies (SeBluCo study) [27] that have 
in preliminary findings determined an antibody prevalence 
The CORONA- 
MONITORING lokal study 
surveys the population  
antibody status at four  
locations in Germany that 
have been particularly 
affected by the SARS-CoV-2 
pandemic, and this will 
enable an estimate of  
the local population  
seroprevalence.
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